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Chronic Sleep Disruption Alters Gut 
Microbiota, Induces Systemic and 
Adipose Tissue Inflammation and 
Insulin Resistance in Mice
Valeriy A. Poroyko1,2,*, Alba Carreras1,*, Abdelnaby Khalyfa1, Ahamed A. Khalyfa1, 
Vanessa Leone3, Eduard Peris1, Isaac Almendros1, Alex Gileles-Hillel1, Zhuanhong Qiao1, 
Nathaniel Hubert3, Ramon Farré4,5,6, Eugene B. Chang3 & David Gozal1
Chronic sleep fragmentation (SF) commonly occurs in human populations, and although it does 
not involve circadian shifts or sleep deprivation, it markedly alters feeding behaviors ultimately 
promoting obesity and insulin resistance. These symptoms are known to be related to the host gut 
microbiota. Mice were exposed to SF for 4 weeks and then allowed to recover for 2 weeks. Taxonomic 
profiles of fecal microbiota were obtained prospectively, and conventionalization experiments were 
performed in germ-free mice. Adipose tissue insulin sensitivity and inflammation, as well as circulating 
measures of inflammation, were assayed. Effect of fecal water on colonic epithelial permeability 
was also examined. Chronic SF-induced increased food intake and reversible gut microbiota changes 
characterized by the preferential growth of highly fermentative members of Lachnospiraceae and 
Ruminococcaceae and a decrease of Lactobacillaceae families. These lead to systemic and visceral 
white adipose tissue inflammation in addition to altered insulin sensitivity in mice, most likely via 
enhanced colonic epithelium barrier disruption. Conventionalization of germ-free mice with SF-derived 
microbiota confirmed these findings. Thus, SF-induced metabolic alterations may be mediated, in 
part, by concurrent changes in gut microbiota, thereby opening the way for gut microbiome-targeted 
therapeutics aimed at reducing the major end-organ morbidities of chronic SF.
Fragmented sleep (SF) occurs frequently in many highly prevalent disorders, e.g., obstructive sleep apnea (OSA), 
and leads to excessive daytime sleepiness as well as to cognitive, mood, and neurobehavioral deficits1. SF also 
imposes adverse metabolic consequences, such as increased appetite and food intake that ultimately promote the 
emergence of obesity and metabolic dysfunction, the latter further exacerbating sleep disruption2,3. Indeed, even 
before the SF-induced increase in somatic weight gain occur, evidence of altered insulin sensitivity is apparent 
in adipose tissues and has been ascribed to increased SF-induced oxidative stress and inflammatory processes4. 
However, the mechanisms underlying the emergence of visceral white adipose tissue (VWAT) inflammation in 
the context of disrupted sleep are unclear and could potentially involve alterations in the gut microbiome.
The gut microbiome5 has been identified as playing a significant role in the phenotypic characteristics of host, 
immunity, metabolism6, and circadian clock function7. Furthermore, complex disorders previously attributed 
to lifestyle8–10 are now claimed as microbiota-related. In a now large and ever increasing number of human and 
animal studies changes in gut microbial communities have been mechanistically linked with adiposity8,11. The 
cumulative evidence from these studies has led to a generalized consensus that gut microbiota mediates an energy 
intake12, and play a critical role in the development of the “metabolic phenotype”11. We have recently demon-
strated that exposures to intermittent hypoxia mimicking OSA lead to profound alterations in gut microbiota13. 
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Therefore, we hypothesized that the disrupted patterns of sleep that characterize OSA, as well as many other sleep 
disorders, may be linked to obesity and metabolic phenotypes via changes in gut microbial communities. Here 
we explored the effects of SF on gut microbiome and the downstream metabolic implications of such effects in 
visceral adipose tissues.
Results
SF for 4 weeks increases food intake, insulin resistance, and VWAT mass and inflammation 
without body weight changes. Mice exposed to SF exhibited increased food intake that began within 
a few days following the initiation of SF and was sustained throughout the duration of SF exposure (Fig. 1a). 
However, upon cessation of SF at 4 weeks, the increased food intake rapidly reverted back to baseline during 
the subsequent 2 weeks of recovery (Fig. 1a). As previously reported, no significant differences in body weight 
were present upon completion of the SF exposures at 4 weeks (27.2 ± 1.6 g in SF and 27.1 ± 1.5 g in CTL mice; 
Figure 1. SF exposure increases food intake over time, which returns to baseline upon discontinuation of SF 
(a), along with increased VWAT mass (b), systemic (c) and VWAT insulin resistance (d). Representative FACS 
plots showing the gating strategies used for macrophages (e), neutrophils (f), and M1 macrophages (g). After  
4 weeks of SF exposures, increases in VWAT macrophages (h), neutrophils (i), and M1 macrophages (j) emerged, 
and returned to within CTL values in SF 2R mice.
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p > 0.05)2,4. However, SF mice exhibited significantly increased visceral fat mass at 4 weeks of SF when compared 
to CTL. Furthermore, visceral fat mass returned to levels observed in controls 2 weeks after discontinuation of SF 
(Fig. 1b). Fasting HOMA values were higher in SF-exposed mice and returned to CTL values following 2 weeks 
of recovery (Table 1; Fig. 1c). Ex vivo assessment of adipocyte insulin sensitivity revealed reduced p-AKT/AKT 
ratios in VWAT adipocytes derived from SF 4w-exposed mice when compared to CTL mice, but such differences 
were abrogated in SF 2R adipocytes (Fig. 1d).
In conjunction with SF-induced increase in visceral white adipose tissue (VWAT), increased numbers of leu-
kocytes, primarily consisting of neutrophils and macrophages, the latter particularly exhibiting M1 polarity, were 
identified after 4w SF, and nearly returned to CTL values in 2WR SF mice (Fig. 1e–i). Such changes were present 
across several VWAT depots (data not shown) but were particularly prominent in mesenteric VWAT (Fig. 1e–i). 
In parallel with such changes, 4w SF increased expression of LBP in VWAT adipocytes and macrophages (4.3 ± 0.6 
and 5.8 ± 1.4 fold compared to CTL; n = 7; p < 0.0001), as well as increases in IL-6 (3.7 ± 0.8 and 7.4 ± 2.6 fold; 
n = 7; p <  < 0.00010), and NGAL (4.4 ± 1.1 and 6.8 ± 2.0 fold; n = 6; p < 0.0001), with all three genes returning 
to CTL levels after 2-week recovery, except for IL-6 mRNA expression in macrophages which although decreased 
(1.9 ± 0.4 fold; n = 6; p < 0.001) in respect to SF 4w, remained elevated compared to CTL (p < 0.01). Similarly, 
plasma LBP, NGAL, and IL-6 protein levels were increased in 4w SF mice, and except for IL-6 returned to baseline 
levels (Table 1). A significant association between pAKT/AKT insulin slopes in mesenteric adipose tissues and 
corresponding LBP or NGAL plasma levels emerged (r2:0.47 and r2:0.56, respectively, p < 0.0001).
Microbial community profiling. Regardless of recent debates14 fecal material is widely accepted as a proxy 
for intestinal microbiota studies5,15–17. Accordingly, fecal DNA was used for PCR reactions with universal prim-
ers18. PCR amplicons were sequenced, assembled in operating taxonomic units OTUs, taxonomically annotated, 
and used to assess the structure and membership of the gut microbial community. In total, 7,009,841 sequences 
were recovered and rarefied to 10,000 sequences/sample. Good’s coverage estimation19 showed near complete 
coverage of 0.99 ± 0.002, indicating that 99% of targets were sequenced at least twice. Sequences were assembled 
in 5995 OTUs which gains 232 ± 27.8 OTUs per sample. OTUs were attributed to 12 phyla, 26 classes, 44 orders, 
74 families, and 117 genera (Supplementary materials 1s).
To assess the effect of SF, the table of OTU abundances was used to calculate distances between samples using 
Bray-Curtis dissimilarity measure20. OTU abundances were averaged by treatment/day of collection, standard-
ized, square root transformed and used to calculate dissimilarity matrix for Principal Coordinate analysis (PCoA). 
The Group-averaged clusters from Bray-Curtis similarities (“a”-“d”) were formed at 68% (arbitrary cut-off) sim-
ilarity level and superimposed on PCoA plot, as described in Clarke and Warwick (2001)21. Superimposition 
demonstrated alteration of microbial community that occurred within 2 weeks of SF exposures (Fig. 2a). The 
clusters are significantly different from each other (ANOSIM, p < 0.001) and consist of samples: “a” - samples 
collected during early acclimation period, i.e., 7 and 5 days before SF treatment was initiated; “b” - CTL and SF 
samples spanning the period from late acclimation (3 and 1 days before SF treatment was initiated) and from 1–2 
weeks of experiment; “c” - SF samples 2–4 weeks of treatment, and “d” - CTL samples weeks 3–6, one SF sample 
of day 28 (week 4) and SF-recovery samples week 5–6. However, while SF treatment altered community structure, 
the complexity of microbial populations remained unchanged between samples from cluster “c” and matching 
samples from clusters “b” and “d” (Simpson diversity index in the two-sided t-test, p = 0.29).
METASTATS comparison identified differentially abundant bacterial taxa in SF (samples from cluster “c”) 
and CTL groups (matching samples from clusters “b” and “d”). At the level of phylum, Firmicutes increased in 
abundance after SF treatment by 20%, while Bacteroidetes and Actinobacteria, were reduced by 20% and 50% 
abundance, respectively (METASTATS, p < 0.05) (Fig. 2b). At greater taxonomic resolution, SF exposure was 
associated with the expansion of Lachnospiraceae and Ruminococcaceae families, with addition of several line-
ages from class Clostridia and order Clostridiales. In contrast, during SF exposure families Lactobacillaceae and 
Bifidobacteriaceae were suppressed nearly 2-fold (Fig. 2c).
In an attempt to identify most prominent taxa affected by SF, we studied OTUs from cluster “b” (abundances > 1%), 
and found 5 OTUs with abundances increased by > 2-fold when compared to the CTL group (METASTATS, 
p < 0.02; Table 2). These OTUs were attributed to the order of Clostridiales, with 80% belonging to the family of 
Lachnospiraceae. The decrease of abundance > 2-fold in response to SF (Table 2) is shown by other 5 OTUs, one 
of which was annotated as Lactobacillaceae genus. No differentially abundant OTUs from Bifidobacteriaceae and 
Ruminococcaceae families exhibited the same degree of alterations. This finding further justified our attention 
on the dynamics of Lachnospiraceae and Lactobacillaceae families (Fig. 2d,e). The abundance of Lachnospiraceae 
family increased after initiation of SF treatment (p < 0.002) and returned to control levels when the SF exposures 
SF 4w (n = 12) SF 2R (n = 12) CTL (n = 12)
HOMA-IR 8.7 ± 2.4§ 3.9 ± 0.9 3.6 ± 0.6
Leptin (ng/ml) 0.89 ± 0.42§ 0.73 ± 0.32 0.78 ± 0.28
NGAL (ng/ml) 146.3 ± 39.4§ 68.9 ± 11.4 59.4 ± 9.6
LBP (ng/ml) 58.9 ± 14.2§ 23.6 ± 6.8 21.4 ± 6.5
IL-6 (pg/ml) 9.2 ± 3.4§ 7.5 ± 2.9¥ 3.6 ± 0.8
Table 1.  Systemic insulin resistance, leptin and inflammatory markers following SF and recovery. §SF 4w 
vs. SF 2R or CTL – p < 0.01; ¥SF 2R vs. CTL – p < 0.05.
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Figure 2. The properties of the gut microbial community are altered by SF treatment. (a) PCoA plot 
demonstrates structural changes in microbial communities over the period of 7 weeks, introduced by SF exposure 
followed by 2 weeks of sleep recovery. The major clusters (a–d) of individual points (averaged microbiota per 
treatment per day) were outlined by 68% similarity between data points (Bray-Curtis index), ANOSIM test confirms 
separation (p = 0.001). The data points are labelled by the week of experiment (0 week - a week of acclimation; 1–4 
weeks - SF exposure, 5–6 week – recovery). (b) Differentially abundant bacterial phyla and (c) families in SF and 
CTL samples at weeks 2–4 (METASTATS, p < 0.02). (d,e) The abundance of Lachnospiraceae and Lactobacillaceae 
family members is different between SF and CTL groups at weeks 2–4 (W2–4) (*p < 0.002), but not at the initiation 
of treatment (INI) and at the end of recovery period (2R). Boxplots represent median and 25–75 percentiles.
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were ceased (p = 0.44). In contrary Lactobacillaceae demonstrated opposite reaction the decrease of abundance 
during SF treatment (p = 0.0033) and return to CF level after 2 weeks of recovery (p = 0.17).
Phenotype Arrays. The basis for physiological profiling is the fact that structurally and functionally different 
microbial communities metabolize different sets of substrates22. To infer information about community dynam-
ics, the rates of aerobic and anaerobic substrate utilization in CTL and SF microbial communities (n = 5/time 
point) were compared using fecal specimens collected before the start of SF treatment, at 1, 2, 3, and 4 weeks of 
SF and two weeks after cessation of SF treatment (2R). The results of PERMANOVA comparisons indicated SF 
did not affect that aerobic community metabolism. However, anaerobic microbial metabolism was significantly 
altered after 4 weeks of SF (PERMANOVA, p = 0.032), as illustrated by the increased separation of samples over 
the first principal coordinate (PC1) after 4-weeks of SF treatment. These differences were absent at 2R, indicat-
ing complete recovery of microbiota in the ability to metabolize available substrates (PERMANOVA, p = 0.84) 
(Fig. 3a). The comparisons of third quartiles of OD values across aerobic and anaerobic plates at 4 weeks con-
firmed that SF had no effect on aerobic, but suppressed anaerobic substrate utilization (Wilcoxon test, aerobic 
p = 0.2, anaerobic p = 0.017; Fig. 3b). Additional analysis identified significant changes at 4W SF in the metabolic 
rates associated with anaerobic utilization of 6 substrates (Fig. 3c). Microbial communities at 4W of SF decreased 
utilization of D-mannose and citric acid (both > 400-fold reductions), gentiobiose, β -Methyl-D-glicoside and 
propionic acid (all reduced 3–4 fold). SF microbiota demonstrated increased anaerobic resistance to surfactant 
Niaproof 4 (p = 0.004), but CTL communities did not have such resistance (Supplementary Material 2s).
“Fecal water” from stool samples after 5 weeks of SF exhibits enhanced colonic epithelium 
barrier disruption. In vitro experiments were performed to determine effects of gut microbiota on intestinal 
barrier. These effects may underlie SF-related increases in LBP levels. Trans-epithelial electric resistance (TER) 
measurements after treatment with PBS (vehicle control), samples of SF or CTL “fecal water”, a preparation of 
microbial-void water-soluble parts of fecal metabolome and proteome, were applied to confluent monolayers 
of both Human Normal Colon Cells (HNCC) and CACO-2 cells. Normalized resistance tracings in HNCC cell 
monolayers (Fig. 3d) showed rapid decreases in TER induced by contact with “fecal water” samples from SF, but 
not from CTL mice. Similar experiments with CACO-2 cells confirmed the immediate and sustained decreases in 
TER induced by SF “fecal water” (data not shown).
Conventionalization of SF and CTL cecal microbiome in germ-free mice. Conventionalization 
experiments with microbiota from mice exposed to 4W of SF vs. CTL showed increased food intake (3.7 ± 0.7 
vs. 3.2 ± 0.6 g/day/mouse; p = 0.05), but no differences in body weight gain or VWAT mass were apparent after 2 
weeks. However, conventionalization with SF microbiota elicited markedly enhanced inflammatory responses in 
mesenteric and epididymal fat tissues when compared to either conventionalization with microbiota from CTL 
mice or mice that remained germ-free. These responses were characterized by increases in overall macrophage 
counts (CTL: 4.9 ± 2.7 vs. SF: 17.8 ± 6.7%% of live cells; p < 0.001; n = 8/group; non-conventionalized controls: 
3.8 ± 2.1%; n = 4), neutrophils (CTL:16.6 ± 4.7% vs. SF: 49.2 ± 11.2% of CD11b+ cells; p < 0.001; n = 7/group; 
non-conventionalized controls: 11.7 ± 4.1%; n = 4), and a major shift toward M1 macrophage polarity as illus-
trated by the proportion of CD11c+ macrophages among CD11+ cells (CTL: 18.7 ± 5.1% vs. SF: 42.1 ± 10.2%; 
p < 0.001; n = 8/group; non-conventionalized controls:12.8 ± 3.1%; n = 4). Furthermore, increases in systemic 
HOMA-IR and systemic inflammatory markers (Table 3), as well as reduced pAKT/AKT insulin sensitivity in 
the epididymal fat of mice conventionalized with SF-derived microbiota emerged (Fig. 3e) thus recapitulating SF 
metabolic phenotype.
Discussion
This study shows that long-term SF exposure (4 weeks) during the sleep period in mice leads to increased visceral 
fat mass, VWAT inflammation, as wells as systemic insulin resistance and increased leptin plasma levels. These 
effects are reversible upon cessation of SF exposure. Furthermore, increased numbers of M1 macrophages and 
neutrophils in VWAT, particularly in mesenteric adipose tissues, along with elevated IL-6, NGAL, LBP levels, 
were present in SF-exposed mice, suggesting a potential gut-derived transfer of microbially-produced substances 
to elicit an inflammatory response. Analyses of the gut microbiome further revealed that SF induces temporally 
OUT* CTL SF
CTL to SF 
fold change p-value Taxonomic attribution
Otu00025 0.013 ± 0.003** 0.003 ± 0.001 ↓ 4.3 0.007 Lactobacillaceae genus
Otu00036 0.007 ± 0.015 0.015 ± 0.002 ↑ 2.14 0.002 Lachnospiraceae, unclassified genus
Otu00028 0.005 ± 0.016 0.016 ± 0.003 ↑ 3.2 0.025 Lachnospiraceae, unclassified genus
Otu00037 0.005 ± 0.012 0.012 ± 0.002 ↑ 2.4 0.001 Lachnospiraceae, unclassified genus
Otu00011 0.004 ± 0.029 0.029 ± 0.008 ↑ 7.25 0.005 Lachnospiraceae, unclassified genus
Table 2.  Significantly different OTUs identified in CTL and SF groups. *OTUs exceeding 2 folds of change 
and annotated to the genus level are listed. **Median relative abundance ± standard error.
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coordinated changes in microbial communities and in their substrate processing properties, signifying a shift in 
microbial function despite a relatively minor, albeit significant effect on overall microbial community structure. 
Figure 3. (a) The effect of SF on anaerobic substrate utilization increases separation of samples over the first 
principal coordinate (PC1) at 4-weeks of exposure, separation decreases after 2 weeks of recovery. (b) Boxplots 
compare the third quartiles of OD590 values across aerobic and anaerobic plates and shows no effect of 4w 
SF on aerobic microbial substrate utilization and inhibitory effect on anaerobic substrate utilization. (c) The 
volcano plot demonstrates the decrease of anaerobic utilization of 5 substrates in 4w SF microbial community. 
(d) Marked disruption of epithelial cell barrier occurred in monolayers of Human Normal Colon Cells (HNCC) 
exposed to SF-derived, but not to CTL-derived “fecal water” as demonstrated by mean TER changes. (e) VWAT 
insulin sensitivity is reduced in germ-free mice after conventionalization with SF-derived cecal microbiota as 
compared to CTL-derived or germ-free mice.
TF-SF (n = 8) TF-CTL (n = 8) Non-TF Germ-Free (n = 4)
P-value (TF-SF vs. 
TF-CTL or Non-TF)
HOMA-IR 6.2 ± 2.5 3.4 ± 1.4 3.4 ± 1.5 < 0.01
NGAL (ng/ml) 198.4 ± 46.8 77.6 ± 35.7 64.3 ± 45.1 < 0.01
LBP (ng/ml) 112.6 ± 23.8 44.9 ± 22.1 27.9 ± 20.2 < 0.01
IL-6 (pg/ml) 35.4 ± 8.4 19.5 ± 7.2 12.6 ± 5.5 < 0.05
Table 3.  Systemic insulin resistance and inflammatory markers following conventionalization of germ-
free mice by SF and CTL fecal microbiome.
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Conventionalization of germ-free mice with microbiota from SF and CTL mice recapitulated the systemic and 
adipose tissue inflammatory responses and metabolic alterations induced by SF. Taken together, chronic pertur-
bations in sleep continuity, mimicking highly prevalent human sleep disorders, elicit systemic and adipose tissue 
inflammation and disruption of metabolic homeostasis that, in part, mediated by SF-induced alterations in gut 
microbiota.
Some methodological considerations deserve a comment. First, the sleep fragmentation procedures used 
herein afford reproducibility, lack of measurable increases in stress hormones or circadian disruption, the absence 
of human contact, and preserved social settings, while allowing for ad libitum food and water access, all of which, 
could independently contribute to the gut microbiome alteration2. Furthermore, we have also shown that the 
current model of SF does not curtail sleep duration and that the episodic arousals in the context of preserved 
sleep duration primarily manifest as increased sleep propensity, thereby closely mimicking several human sleep 
disorders23. We should also point out that chronic SF induces an increase in tissue level of tumor necrosis factor 
α (TNF- α ), and it is possible that the increased systemic levels of this cytokine may operate also as a potent 
pro-inflammatory agent, most likely via activation of the TNF p75 receptor24,25. Alternatively and more akin 
to our current line of thought, gut microbiome changes would represent the initial set of events, which would 
facilitate the occurrence of low-grade bacterial challenges from the gut, thereby prompting immune responses, 
as exemplified by increased LBP and NGAL plasma and adipose tissue expression levels, with the latter changes 
being particularly prominent in the mesenteric VWAT. Nevertheless, it remains unclear how SF in the host 
induces such changes in the gut microbiome. It is possible that SF may alter gastrointestinal tract motility or the 
gut milieu, or possibly act via vagally mediated effects26. Notably, children with obstructive sleep apnea, a highly 
prevalent condition associated with chronic SF, exhibit markedly elevated circulating levels of LBP, particularly 
when obesity is concurrently present27. Thirdly, we should stress that we opted not to implement administration 
of a high fat diet or to employ transgenic mice with heightened susceptibility to obesity, since we wished to exam-
ine the isolated effect of disrupted sleep on the gut microbiome in isolation, rather than potentially confound our 
findings with changes in microbial communities that derive from dietary or genetic manipulations28–30.
Current experiments illustrate not only the emergence of VWAT inflammation and insulin resistance as 
induced by chronically disrupted sleep, but also reveal the potential reversibility of such metabolic perturba-
tion upon discontinuation of SF. However, it remains unclear whether such reversibility is circumscribed to the 
temporal window preceding the emergence of frank obesity2 or will still be operationally viable even at more 
advanced stages of SF duration, once that obesity has occurred and settled in. Notwithstanding, the current con-
ventionalization experiments clearly indicate that SF-induced alterations in fecal microbiota promote increased 
colonic epithelial barrier disruption that leads to systemic and tissue inflammatory phenotypic changes and 
concurrent emergence of metabolic dysfunction. Indeed, evidence for infiltration of M1 polarized macrophages 
and neutrophils are early processes in the context of high fat diet-induced insulin resistance31, and most likely 
reflect the changes induced by SF on the microbiome-gut permeability axis. Furthermore, the induction of VWAT 
inflammatory changes coincided with the emergence of systemic and tissue insulin resistance, as illustrated by the 
increases in HOMA-IR and by the reduced pAKT/AKT responses to exogenous insulin in VWAT.
Modern studies have provided conclusive evidence that host obesity alters gut microbiota8,32 and that, in turn, 
gut microbiota mediate the occurrence of metabolic disorders11. The microbiocentric paradigm mechanistically 
connected consumption of a high-fat diet with metabolic disorders via development of metabolic endotoxemia 
(increased level of LPS in blood circulation)29,33. Recent work has indicated the synergistic effect of circadian 
perturbations on the high fat diet-microbiome metabolic deregulation7. In turn, our study demonstrated that SF 
experiments preserving the circadian light zeitgebers affect gut microbiota by disturbing community structure, 
as clusters “b” and “c” separate at day 9 (Fig. 2), and inducing the emergence of metabolic phenotype in conven-
tionalization experiment. We demonstrated that SF treatment changes the ratio of Firmicutes to Bacteroidetes 
(FB-ratio) from 1 in CTL to 1.7 in SF. A similar trend was previously associated with the development of obe-
sity16 and low-grade inflammation34. Even though the functional significance of FB ratio is disputable35–37 it sets 
an important indicator of structural modifications of gut microbiota. In our study, the expansion of Firmicutes 
was associated with an increase in abundance of Lachnospiraceae and Ruminococcaceae bacterial families. These 
highly fermenting bacteria are important for degradation of plant-derived fibers38, production of short chain fatty 
acids7,39, and, hence, the increase of energy harvest40–43. The growth of Firmicutes could be explained by the noted 
increase in food intake and accompanied by the changes in anaerobic substrate utilization. Indeed, all impacted 
bacterial families (Lachnospiraceae, Ruminococcaceae, Lactobacillaceae, and Bifidobacteriaceae) are comprised 
of anaerobes. The increased food intake cannot be the only single factor explaining the bacterial dynamics26 
in our study, as SF microbiota had a tendency to converge to SC state (day 28) (Fig. 2a), while the food intake 
still remained elevated. The mechanisms underlying this phenomenon warrant future investigation in experi-
ments involving paired-fed mice. Nevertheless, the functional properties of SF microbiota, remained abnormal, 
as demonstrated consequently by phenotype arrays, ECIS and the conventionalization experiments.
Unmistakably, the conventionalization with SF microbiota conveyed the features of metabolic phenotype to 
naïve recipients. However, the absence of body weight and VWAT mass gains in these experiments, although 
anticipated since such changes require more extended exposures to SF than 2 weeks2, lead to the assumption that 
the complete SF-metabolic phenotype is the result of more than a single pathway, the symptoms of obesity and 
inflammation deserving separate consideration. To offer a unifying hypothesis, we speculate that the SF-related 
excessive food intake leads to body weight gain and induces changes in gut microbiota; the latter, mediates the 
emergence of an inflammatory phenotype via mechanisms associated with low grade systemic endotoxemia. In 
turn, SF altered microbiota will transfer such inflammatory phenotype to germ-free recipients. Alternatively, 
as mentioned it is very likely that 2 weeks post-conventionalization constitute an insufficient period of time to 
achieve excessive weight gain, since weight gain during SF exposures usually requires 4–5 weeks2.
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The altered gut community (elevated Lachnospiraceae and decreased Lactobacteriaceae) was complemented by 
elevated IL-6, NGAL, and LBP levels indicating induction of inflammatory processes perhaps due to the leakage 
of microbial products into circulation. In earlier studies, the pro-inflammatory effect of innate Gram-positive 
bacteria (Firmicutes) was demonstrated in a mouse model of dextran sodium sulfate (DSS)-induced colitis44. The 
study denoted a prominent contribution of bacteria from the flagellated Lachnospiraceae family in the develop-
ment of intestinal inflammation44,45. The bacterial flagellin, recognized by TLR5 at the basolateral sites of colonic 
epithelial cells, induces CCL2 secretion and recruitment of inflammatory macrophages46. The contribution of 
Lachnospiraceae to the onset of metabolic dysfunction was additionally confirmed in colonization experiments 
with germ-free ob/ob mice47. In germ-free recipients, colonization with Lachnospiraceae strain AJ110941 reca-
pitulated the metabolic phenotype and caused the increase in fasting blood glucose, increase of liver and mes-
enteric adipose tissue weight, decreased plasma insulin levels and HOMA-β values, leading to speculation that 
Lachnospiraceae facilitate translocation of LPS from the alimentary tract into the blood47. This speculation is 
further supported by the observed decline of barrier protective bacteria (Lactobacteriaceae family29,48,49) and 
by our in vitro ECIS experiments, that confirms the barrier disruptive properties of fecal water prepared from 
feces of SF exposed mice. Thus, the discovered increase in relative abundance of Lachnospiraceae and loss of 
Lactobacteriaceae during the development of SF-induced metabolic phenotype may have important therapeutic 
implications, seeing that high fat diet-induced metabolic phenotype favorably responds to interventions with 
antibiotics29, pre-biotics50 and pro-biotics48,49.
In summary, chronic sleep disruption leads to increases in fat mass, induces selective alterations in gut micro-
biota that elicit increased gut permeability and concurrent systemic and adipose tissue inflammatory changes 
accompanied by insulin resistance, in both conventional and conventionalized mice. These findings open the way 
for future interventional approaches aimed at restoration of gut microbiota to prevent or palliate the multiple 
end-organ morbidities associated with chronic SF.
Methods
Animals. Adult male C57BL/6J mice from Jackson Laboratories (8-week old, ~22–23 grams; Bar Harbor, ME, 
USA), were housed in groups of five for 2 weeks. Mice were fed normal chow diet and water ad libitum and main-
tained in a 12-h light/dark cycle (light on 7:00 am to 7:00 pm) at a constant temperature (24 ± 1 °C). Mice were 
randomly assigned to sleep fragmentation (SF, n = 30) exposures or sleep control (CTL, n = 30) conditions. Stool 
was collected every other day for 42 days in a subset of animals (SC (n = 6), SF (n = 7), and at day 28 and 42 the 
entire available population was sampled. Animal experiments were performed according to protocols approved 
by the IACUC of the University of Chicago (72043, 72078).
Sleep Fragmentation Paradigm. The sleep fragmentation was induced as previously described23. Briefly, 
it employs intermittent tactile stimulation using a near-silent motorized horizontal bar sweeping just above the 
cage floor from one side to the other. Since on average 30 episodes of arousal per hour occur in patients with 
severe OSA (i.e., every 2 min), our aim was to mimic closely the more severe disease condition, and thus, a 2-min 
interval between each sweep was implemented during the light period (7:00 am to 7:00 pm). SF was implemented 
for a period of 4 weeks (SF 4w) and then discontinued in a subset of mice (n = 5) for a recovery period of 2 weeks 
(SF 2R).
Food consumption and body weight. Food consumption per cage was recorded daily and body weight 
was measured every other day at the middle of the light period. Food consumption was calculated by dividing the 
daily cage chow utilization by the number of mice in the cage. Body weight gain was determined by subtracting 
the body weight on the first day of SF exposure from the body weight on subsequent days.
Glucose tolerance test (IGTT). IGTT was performed after 4-week of exposure (SF 4w), following the 
2-week recovery period (SF 2R), and in CTL. Mice were injected with glucose (2 mg/g body weight, i.p.) after 
3 hours of fasting. Water was available during the fasting period. Blood glucose was measured using an OneTouch 
Ultra 2 glucometer (Life Scan; Milpitas, CA). Blood samples were collected from the tail vein at 0, 4, 15, 30, 60, 90 
and 120 min. Glucose response during IGTT was evaluated by estimating the total area under the glycemia index 
vs. time curves.
Insulin tolerance test (ITT). Mice were injected intraperitoneally with humulin (0.25 U/kg of body weight) 
after 3 hours of fasting in both SF 4w, SF 2R, and CTL mice. Blood was collected via the tail vein from each mouse, 
and blood glucose was measured using an OneTouch Ultra2 glucometer (Life Scan; Milpitas, CA). Blood sam-
ples for insulin determination were obtained from the cut tip of the tail at 0, 4, 15, 30, 60 and 120 min following 
injection. Insulin resistance was assessed using the homeostasis model assessment (HOMA-IR) equation (fasting 
insulin × fasting glucose/22.5). ITT glycemic trajectories were also analyzed for differences in insulin sensitivity 
as previously described51. Mice undergoing ITT were not assessed for IGTT and vice-versa.
Insulin Sensitivity Assay. Adipocyte insulin sensitivity was assessed in adipocytes, derived from visceral 
fat tissue, using Western blotting for phosphorylated and total Akt (antiphospho-Akt [Ser473] and anti-Akt; Cell 
Signaling Technology, Danvers, MA) as previously described52.
Isolation of stromal-vascular fraction (SVF) and flow cytometry analysis. Isolation and analysis 
were performed as described previously3,4. Adipose tissue macrophages were defined as CD11b+ cells, from 
which M1 and M2 macrophages were identified as CD11c+ or CD206+ cells, respectively. Neutrophils identified 
as CD11b+ and Ly6Chigh+ cells53. All antibodies were from Biolegend (San Diego, CA).
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Leptin, lipopolysaccharide-binding protein (LBP), neutrophil gelatinase-associated lipocalin 
(NGAL) and IL-6 expression and plasma levels. Plasma leptin and IL-6 levels were measured using 
commercial kits (Millipore; St. Charles, Missouri, USA and Biolegend, San Diego, CA, USA, respectively) as 
described by the manufactures. NGAL is a 25-kDa secretory glycoprotein that belongs to the lipocalin fam-
ily and is expressed in many tissues and cells in addition to adipose tissue, including leucocytes (macrophages 
and neutrophils). NGAL expression is induced by various pro-inflammatory stimuli through Nuclear factor-kB 
activation, and plasma levels reflect not only inflammatory status elicited by LPS or other bacterial products but 
are also associated with insulin resistance54. Similarly, lipopolysaccharide-binding protein (LBP) is released by 
various cells including macrophages and adipocytes and is associated with insulin resistance55. LBP and NGAL 
assays were performed using commercial ELISA assays (Cell Sciences, Canton, MA, USA, and R&D Systems, 
Minneapolis, MN) according to the manufacturer’s instructions. Total RNA was isolated from VWAT adipocytes 
and macrophages using automated RNA extraction (Promega, Madison, WI) and quantified on a Nanodrop 2000 
(Ambion, Austin, TX, USA). Expression of LBP and NGAL was examined using RT-PCR using specific TaqMan 
primers. Quantitative RT-PCR (qRT-PCR) was performed for mRNAs in triplicate in ABI PRISM 7500 System 
(Applied Biosystems, Foster City, CA, USA). Ribosomal 18S rRNA was used as a reference gene to normalize the 
expression ratios. The mean cycle number (Ct) values of the 18S Ct and the gene of interest Ct were calculated. 
The relative expression of the gene of interest was calculated using the 2-Δ Δ Ct method.
16S rRNA gene tags analysis. Fecal DNA was isolated using Stool Fast Mini Kit (Qiagen). The 16S 
rRNA tag libraries were generated using the set of indexed primers (V4 hypervariable region) and sequenced on 
Illumina MiSeq platform18. The unidirectional reverse sequences (mean length 150 bp) were collected, processed 
and annotated vs. RDP database (v.9)56 using Mothur software57 as described58,59. Metastats software60 was used 
to determine differentially abundant taxa; PCoA and ANOSIM tests (Primers 6)61 were used to compare groups 
and time points.
Phenotype Arrays. Metabolic arrays (Gen3 MicroPlates (BIOLOG Inc., CA)) were used to determine sets 
of substrates metabolized by microbial communities of CTL and SF treated animals. One freshly collected fecal 
pellet was dissolved in 1 ml of inoculation fluid IFa7. The homogenate was centrifuged briefly to remove debris; 
supernatant (15 μ l) was used to initiate aerobic and anaerobic growth in MicroPlates. Anaerobic plates were pre-
pared, inoculated and incubated in an anaerobic chamber (Coy, Grass Lake, MI) at 37 °C, while aerobic plates 
were handled and incubated at room air. Optical density (OD 590 nm) was measured at the end of 18 hours 
incubation. The OD values for 96 substrates were log10 transformed and normalized separately across anaerobic 
and aerobic plates. The Euclidian distances matrix between samples was calculated and used in PERMANOVA 
test to estimate the significance of SF effect. Nonparametric Wilcoxon test was used to determine differentially 
metabolized substrates.
Conventionalization Experiments. The freshly excised ceca of SF and CTL mice were prepared as pre-
viously described8 and functionally active microbiota was transferred into germ-free (GF) recipient mice by oral 
gavage (200 μ l cecal content in the sterile saline buffer). GF mice conventionalized with SF or CTL microbiota 
were euthanized at 2 weeks post-colonization. Their plasma and VWAT were processed as described above.
Electrical cell impedance (ECIS). The “fecal water”, a preparation of water-soluble parts of fecal metab-
olome and proteome, was used to determine barrier disruptive properties of gut microbiota that may underlie 
endotoxemia. Fresh fecal samples from C57BL/6J CTRL mice and mice exposed to SF for 5 weeks were pooled 
by cage and mixed in PBS to final concentration of 1 mg/ml (w/v), cleared by centrifugation (1 min, 5,000 rpm), 
filtered using 20 μ m membrane filter (Millipore), and applied (15 μ l per well; 10% (v/v)) to ECIS system (Applied 
Biophysics, Troy, NY) to determine change of electrical resistance across monolayers of CACO-2 (ATCC, 
Manassas VA) and Normal Human Colon Cells (NHCC) (Applied Biological Materials Inc. Canada).
Statistical analysis. All values are expressed as mean ± standard deviation (SD). Analyses of variance pro-
cedures followed by post-hoc tests and Student t tests were used to compare the results between SF 4w, SF 2R, and 
CTL groups. In all cases, a two-tailed p-value of <0.05 was considered to achieve statistical significance.
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